Novo Nordisk faces formidable challenges from Eli Lilly and new rivals, but its first-mover advantage and expanded ...

StockNews.com upgraded shares of Novo Nordisk A/S (NYSE:NVO – Free Report) from a buy rating to a strong-buy rating in a report released on Thursday. A number of other analysts have also recently ...

Novo Nordisk A/S, Apollo Global Management, and Blackstone are the three Growth stocks to watch today, according to MarketBeat’s stock screener tool. Growth stocks are shares in companies that are ...

Short sellers increased their bets against the broader healthcare sector in February vs. January, and Moderna remained the ...

In my last column about the Novo Nordisk Foundation, I wrote about the company’s efforts in anti-microbial resistance, an example of an area where impact investment was necessary to combat ...